UPDATE: Morgan Stanley Reinstates Bristol-Meyers With Equal-Weight $60 Tgt Sees 'potential for earnings upside in the near-term, driven by bigger/faster cost synergy realization, balanced by patent erosion in mid-late 2020s and uncertainty about pipeline'